Stock comparison
Mettler-Toledo International
Taysha Gene Therapies
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
TSHA
Taysha Gene Therapies
Market cap
$1.37B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | TSHA | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 41D | MTD |
| Benjamin Graham | 65B | 56D | MTD |
| Philip Fisher | 63C | 61C | MTD |
| Peter Lynch | 66B | 5F | MTD |
| Joel Greenblatt | 68B | 2F | MTD |
| Charlie Munger | 74B | 57D | MTD |
| Terry Smith | 70B | 58D | MTD |
Side-by-side metrics
| Metric | MTD | TSHA |
|---|---|---|
| Market cap | $22.29B | $1.37B |
| P/E (TTM) | 25.3x | - |
| EV/EBIT | 21.6x | - |
| ROIC (TTM) | 36.09% | -47.3% |
| Gross margin | 57.79% | 88.22% |
| Net margin | 21.4% | -17.38% |
| Revenue CAGR 5y | 2.01% | - |
| EPS CAGR 5y | 6.12% | - |
| Debt / Equity | - | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- ROIC (TTM)36.09%vs -47.3%+176%
- Net margin21.4%vs -17.38%+101%
- Debt / Equity-vs 0.1x+100%
- Market cap$22.29Bvs $1.37B+94%
TSHA leads on
- P/E (TTM)-vs 25.3x+161%
- EV/EBIT-vs 21.6x+147%
- Gross margin88.22%vs 57.79%+34%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.